Press Releases - OXB

Oxford Biomedica and Institut Mérieux Enter into Exclusive Negotiations with Respect to the Proposed Acquisition by Oxford Biomedica of ABL Europe

Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation The Proposed Transaction, would: Provide Oxford Biomedica multi viral vector CDMO capabilities across multiple sites in EU, US and UK… Read More

Oxford Biomedica to host webinar showcasing the TetraVecta™ system

Oxford, UK – 07 September 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces that it will host a webinar on the TetraVecta™ system, the Company’s 4th generation lentiviral vector delivery system, on Monday 2 October 2023. The webinar titled… Read More

Oxford Biomedica expands agreement with Cabaletta Bio; adding new viral vector programme for CD19-CAR T therapies

Oxford, UK – 22 August 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces that it has expanded its License and Supply Agreement (“LSA”) with Cabaletta Bio, Inc. (Nasdaq: CABA) (“Cabaletta Bio”), a Philadelphia-based clinical-stage biotechnology company focused on developing… Read More

Oxford Biomedica launches the TetraVecta™ System

Oxford, UK – 15 May 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the launch of its 4th generation lentiviral vector delivery system, TetraVectaTM. This state-of-the-art technology developed at Oxford Biomedica elevates the quality, potency and packaging capacity of lentiviral… Read More

2023 AGM Notification

London, UK – 5 May 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “the Company” or “the Group”), a quality and innovation-led viral vector CDMO, gives notice that the Notice of Annual General Meeting (“AGM”) together with a copy of the … Read More

2022 Annual Report and Accounts

London, UK – 28 April 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “the Company” or “the Group”), a quality and innovation-led viral vector CDMO, gives notice that the 2022 Annual report and accounts is now available on the “Investors” section of the Group’s website… Read More

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1st May 2023. Ms Patterson has more than 20… Read More

Preliminary results for the year ended 31 December 2022

Enhancing our position as a global quality and innovation-led viral vector CDMO Oxford, UK – 25 April 2023: Oxford Biomedica plc (“Oxford Biomedica” or “the Company”) (LSE:OXB), a quality and innovation-led viral vector CDMO, announces its preliminary results for the year ended 31 December 2022. Dr. Frank Mathias, Oxford Biomedica’s Chief… Read More

Oxford Biomedica confirms no exposure to SVB receivership

Oxford, UK – 13 March 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, notes the statement by the US Treasury, Federal Reserve, and FDIC on 12 March 2023 announcing measures to protect all depositors of Silicon Valley Bank (“SVB”) in the United… Read More

Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023

Dr Mathias brings a wealth of experience in innovation, contract development and manufacturing to Oxford Biomedica Stuart Henderson to take on newly created position of Vice Chair and Dame Kay Davies to become Senior Independent Director Oxford, UK – 20 February 2023: Oxford, UK – Oxford Biomedica (LSE:OXB), a leading gene… Read More

Board Change

Oxford, UK – 27 January 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces a change to the Group’s Board of Directors. Dr. Siyamak (“Sam”) Rasty has informed the Board that he will not be standing for re-election at the Company’s… Read More

Oxford Biomedica to Present at 41st Annual J.P Morgan Healthcare Conference

Oxford, UK – 21 December 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that Stuart Paynter, Chief Financial Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, 11 January 2023 at 4.30pm… Read More